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Pooled Relative Risk for at least one relapse in four trials including all doses was 0.7, 
a non-signiﬁcant RR (95% CI: 0.42–1.17, P  0. 17). Summary RR for at least one 
relapse in two trials in which doses of 3 mg/kg or 6 mg/kg or 300 mg every 4 weeks 
were administered gave a values of 0.5 as a signiﬁcant RR (95% CI: 0.42–0.61, P  
0.0001). The summary RR for at least one new Gd-enhancing lesion was 0.22, a 
non-signiﬁcant RR (95% CI: 0.05–1.01, P  0.051). Three deaths were reported in 
natalizumab group. Comparing adverse events between natalizumab and placebo 
yielded a non signiﬁcant RR of 0.99 (95% CI: 0.96–1.01, P  0.34) for any adverse 
events (n  3), and a signiﬁcant RR of 0.39 (95% CI: 0.29–0.52, P  0.0001) for 
serious adverse events (n  2). A summary RR for withdrawal due to adverse events 
by natalizumab vs. placebo therapy between two trials was 1.43, a non-signiﬁcant RR 
(95% CI: 0.68–3.02, P  0.35). CONCLUSIONS: It seems that using 3 mg/kg or 
6 mg/kg every four weeks is the best experienced method of administration of natali-
zumab for preventing relapse and occurrence of new Gd-enhancing. Further clinical 
trials are still needed.
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OBJECTIVES: Multiple Sclerosis (MS) is a chronic, recurrent, inﬂammatory disease 
with unrelenting attacks from the immune system. It is the major cause of non-
 traumatic disability in young adults. Iran, contrary to the other countries in Middle-
east, is considered to have a high prevalence of MS that mentioned as the National 
disaster in Iran. While much is known about the MS in the world, there is a paucity 
of the feature of MS in Iran. METHODS: In a 6-month cross-sectional study 248 MS 
patients were studied in Iran. Data was collected by employing a 32- item self-admin-
istered questionnaire. Parametric, nonparametric tests and descriptive statistics analy-
sis were applied (p value 0.05). RESULTS: The prevalence and incidence was 
estimated to be 25/100000 and 2.5/100,000, respectively. The patients were diagnosed 
in 2001 onward were more frequently than the patients in1981–1990(40:1). The mean 
age 31.9 o 8.7, the mean onset age 26.3(26.3 o 8:1) and the mean duration of illness 
were 5.6 o 5.3 years. A family history of ms was reported in 11%. The sex ratio was 
3:1(female : male). CONCLUSIONS: In contrast to reports from Caucasians , MS 
Iranian population signiﬁcantly differ with respect to the age, onset age, disease dura-
tion, family history and sex ratio. This might reﬂect the different in some environmen-
tal-genetic factors and life style as well, in this population. Some of our ﬁnding were 
comparable to the so-called “western type” of MS such as : BMI, birth season and 
education stand.
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OBJECTIVES: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) 
approved for the treatment of major depressive disorder (MDD). Following patent 
expiration, venlafaxine is available as generic at a reduced price. We evaluated the 
overall savings to the National Health System (NHS) following venlafaxine’s price 
reduction. METHODS: A simulation model was constructed in Microsoft Excel to 
carry out a Budget Impact Analysis. Three scenarios were hypothesized: the ﬁrst simu-
lation evaluated the potential savings to the NHS following venlafaxine’s price reduc-
tion. The second and third simulations assessed additional potential savings to the 
NHS supposing an increase in the market share of venlafaxine by substitution of dif-
ferent proportions of other branded products namely duloxetine and escitalopram. 
Costs were obtained from IMS Health, efﬁcacy data were derived from the available 
literature. RESULTS: Mean annual treatment cost with venlafaxine decreased from 
a567 to a284 resulting in overall savings to the NHS of more than a44 million per 
year. Treatment switching from escitalopram and/or duloxetine to venlafaxine was 
always a dominant strategy and resulted in a higher number of patients treated more 
efﬁcaciously since venlafaxine performs better in terms of remission and is less expen-
sive. Sensitivity analyses on effectiveness (response) and cost variables conﬁrmed our 
results. CONCLUSIONS: This analysis suggests that extended use of generic venla-
faxine is likely to lead to overall cost savings to the NHS due to its cost-effectiveness 
proﬁle compared with other antidepressants such as duloxetine and escitalopram.
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OBJECTIVES: Previous research identiﬁed hypnotic-users to have a greater risk of 
falls and fractures vs. controls. The objective of this study was to determine the 
economic burden of falls and fractures to managed care among hypnotic users. 
METHODS: A retrospective study was designed using data from a national managed 
care commercial claims database. First time hypnotic-users were identiﬁed using 
pharmacy claims and matched to two controls on gender, region, payer, and age. 
Subjects were followed for 12-months post index-date to capture events and costs of 
falls and fractures identiﬁed using speciﬁc ICD-9-CM and E-codes. Multivariate 
regression models were used to estimate the incremental burden of falls or fractures 
at a per-hypnotic user per year (PHUPY) for a hypothetical managed care plan of 1 
million membership with hypnotic-use rate of 4.5% and stratiﬁed by age-categories: 
young-adults (18–44 yrs), middle-age (45–64 yrs) and elderly (65 yrs). RESULTS: A 
total of 40,549 hypnotic-users and 81,098 controls met the inclusion criteria. Both 
groups were demographically similar (p  0.05) at baseline. Hypnotic-users had higher 
Charlson comorbid index scores (1.07 vs. 0.60, p  0.001) and proportion of balance 
disorders (3.33% vs. 2.18%, p  0.001) compared to controls. For those who had an 
event, the total annual mean direct costs of managing falls and fractures was $2,559 
(95%CI: 2117–3001), and $3294 (95%CI: 2916–3673), respectively, with costs lin-
early increasing with age. Based on hypnotic-use rate of 4.5% and age distribution, 
total hypnotic-users in the hypothetical plan were estimated to be 33,750. Falls/frac-
ture related PHUPY translated into $50 (Range: 24–82), $63 (Range: 39–92), and 
$245 (Range: 28–615) for young, middle-age and elderly hypnotic users. Overall 
burden due to falls/fractures as a consequence of hypnotic use to managed care was 
estimated to be $2,092,500 (Range: 1,451,250–2,801,250) CONCLUSIONS: The 
unintended consequence (i.e. managing falls/fractures) of current hypnotic use may be 
burdensome to a managed care plan.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed gamma-cyclodextrin that bonds with 
rocuronium and vecuronium, leading to reversal of the neuromuscular blockade. The 
objective of this study was to evaluate the budget impact and the cost-effectiveness of 
SGX in the routine reversal of patients with neuromuscular block (NMB) from the 
Spanish National Health System perspective. METHODS: A decision-analytic (DAM) 
and a budget impact model (BIM) was developed to assess the mean treatment costs 
per patient (a2009), life-years gained (LYG), and incremental cost per LYG of SGX, 
the spontaneous reversal and neostigmine/atropine in the reversal of patients with 
NMB. The DAM simulates the probability of experiencing an adverse effect and the 
direct costs produced by each treatment alternative. The BIM accounts for the time 
that SGX could save in the operating room (OR), shortening the time to extubation, 
thereby accelerating the movement of patients in and out of the OR. Clinical data was 
obtained from the clinical trial performed with SGX, the SmPC of each drug and form 
secondary sources. Costs were obtained for Soikos database. RESULTS: In the routine 
reversal of patients, ROCSGX is associated with higher costs than the spontaneous 
reversal or neostigmine/atropine but also with higher LYG. The cost-effectiveness 
range of SGX vs. neostigmine/atropine varies between a13,26 and 4,976 per LYG, 
and vs. spontaneous reversal between a6,880 and 17,657 per LYG. In the BIM, SGX 
could save between 108 and 171 minutes of OR, that would mean that 1 or 2 more 
surgeries could be performed, and a total budget saved between a1400 and 2000 per 
OR per day. CONCLUSIONS: Under the established assumptions, SGX would be a 
cost-effective alternative for the routine reversal of patients with NMB and could be 
a cost-saving strategy due to the increase of the turn over of the OR.
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OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS) is the most common 
form of multiple sclerosis. Beta interferons have been shown to reduce relapse rates 
by a third. The aim of this study is assessing the value of subcutaneous interferon 
beta-1a when compared to other available disease modifying drugs for RRMS patients 
in Spain. METHODS: Pharmacoeconomic model based on subcutaneous interferon 
beta-1a clinical trials efﬁcacy data (relapses and progression of disability both on the 
medium and long run) and local expert panel. This analysis was undergone from the 
Spanish National Health System (SNHS) perspective, included only direct medical 
costs and employed an annual discount rate of 3% on both costs and health outcomes. 
The model provided estimations of cost per avoided relapse and cost per avoided 
progression, as well as probabilistic sensitivity analysis with 1000 Monte Carlo simu-
lations. Budget impact analysis was also undergone to forecast the implications of 
subcutaneous interferon beta-1a increased market share in a 4-year horizon. RESULTS: 
Subcutaneous interferon beta-1a and natalizumab result in the lowest MS relapse rates 
with an estimated cost per avoided relapse of a28,847, a29,918, a36,299, a42,027 
and a55,379 when subcutaneous interferon beta-1a, interferon beta-1b, glatiramer 
acetate, natalizumab and intramuscular interferon-1a are employed. Cost per avoided 
